Literature DB >> 3138228

Investigations of the expression of the cellular src gene product.

J S Brugge1, W Yonemoto, A Lustig, A Golden.   

Abstract

We have examined the expression of the c-src gene product in a variety of embryonic and adult tissues, in peripheral blood cells, and in cells transformed by other tumor viruses, in an attempt to identify the types of cells in which pp60c-src might provide a specific function. These studies have indicated that c-src gene expression is regulated at multiple levels in different cell types and have suggested that pp60c-src is not exclusively involved in the regulation of cell proliferation. The lowest levels of pp60c-src were found in fibroblasts, which have previously served as the standard cell type for comparisons between pp60c-src and pp60v-src. The highest levels of pp60c-src-specific kinase activity were detected in three types of cells: neurons, platelets, and polyoma virus transformed cells. In this report, we will compare the expression of pp60c-src in fibroblasts to that in platelets, neurons, and polyoma virus transformed fibroblasts. In each of the three latter cell types, the c-src gene product displays a unique pattern of expression which can be distinguished from that in fibroblasts (see diagram Fig. 1).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3138228

Source DB:  PubMed          Journal:  Princess Takamatsu Symp


  3 in total

1.  Src interacts with dynamin and synapsin in neuronal cells.

Authors:  A Foster-Barber; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 2.  Src family kinases: at the forefront of platelet activation.

Authors:  Yotis A Senis; Alexandra Mazharian; Jun Mori
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

3.  An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.

Authors:  Sarah Danson; Matthew R Mulvey; Lesley Turner; Janet Horsman; KJane Escott; Robert E Coleman; Sam H Ahmedzai; Michael I Bennett; David Andrew
Journal:  J Bone Oncol       Date:  2019-09-18       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.